Skip to content

Medical emergency? What to do

Immunotherapy for heart failure

3-RXPublished September 6, 20065 min read

Key points

  • World Congress of Cardiology Report - Heart failure (HF) is a complex, progressive clinical syndrome that can result from any structural or functional cardiac disorder, such as coronary artery disease or hypertension (high blood pressure), which impairs the ability of the heart to function properly as a pump.
  • The primary objective of the ACCLAIM study was to evaluate the effects of Celacade immunotherapy on the composite endpoint of mortality or cardiovascular (CV) hospitalization in patients with chronic HF.
  • Celacade immunotherapy has been shown experimentally to down-regulate pro-inflammatory cytokines and increase anti-inflammatory cytokines.
  • Immunotherapy using the Celacade System involves the ex vivo (outside the body) treatment of a 10mL sample of a patient's own (autologous) whole blood with controlled oxidative stress and subsequent intramuscular (IM) administration of the treated sample.

World Congress of Cardiology Report - Heart failure (HF) is a complex, progressive clinical syndrome that can result from any structural or functional cardiac disorder, such as coronary artery disease or hypertension (high blood pressure), which impairs the ability of the heart to function properly as a pump.

As a result of this pump dysfunction, a variety of body mechanisms are activated in an attempt to compensate for this defect. Multiple systems within the body, including the neurohormonal system and the immune system, respond to the HF state. Accumulating evidence indicates that inflammatory cytokines (immune response mediators) play a pathogenic role in the progression of HF by impairing the ability of the heart to contract, inducing excessive hypertrophy (enlargement), and promoting cell death or fibrosis (the formation of fibrous tissue). These mechanisms contribute to the destructive cycle of myocardial (heart muscle) remodeling that is characteristic of chronic heart failure.

The primary objective of the ACCLAIM study was to evaluate the effects of Celacade immunotherapy on the composite endpoint of mortality or cardiovascular (CV) hospitalization in patients with chronic HF. ACCLAIM stands for Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy.

Immunotherapy using the Celacade System is a novel non-drug treatment strategy that targets inflammatory mechanisms contributing to progression of chronic HF not yet addressed by current therapies. This form of immunotherapy exploits the anti-inflammatory response to cells undergoing apoptosis (programmed cell death). The physiological response of the recipient's immune system to apoptotic cells results in a decrease in inflammatory cytokines, and up-regulation of anti-inflammatory cytokines. This combined effect may be especially beneficial to patients with chronic HF, since the inflammation associated with this syndrome reflects an imbalance of the two opposing arms of the cytokine network.

Celacade immunotherapy has been shown experimentally to down-regulate pro-inflammatory cytokines and increase anti-inflammatory cytokines. We have previously shown, in a feasibility study of subjects with moderate to severe HF, that active treatment significantly reduced mortality and hospitalization. Moreover, in a recently completed study of 553 patients with atherosclerosis, this form of immunotherapy resulted in a marked reduction in the inflammatory marker hs-CRP.

The ACCLAIM study enrolled over 2,400 subjects at 177 sites in the US, Canada, Germany, Norway, Denmark, Poland, and Israel. ACCLAIM was the largest trial in HF ever conducted to evaluate a therapy targetting inflammation. At baseline, all subjects were receiving optimal standard therapy for HF including ACE inhibitors or angiotensin receptor blockers, beta-blockers, and aldosterone blocking agents as tolerated.

Immunotherapy using the Celacade System involves the ex vivo (outside the body) treatment of a 10mL sample of a patient's own (autologous) whole blood with controlled oxidative stress and subsequent intramuscular (IM) administration of the treated sample. We hypothesize that oxidative stress, a factor known to initiate apoptosis in white cells, commits the treated cells to undergo apoptosis following IM administration. Within the muscle tissue, the treated cells interact with specific immune system cells (antigen presenting cells) and elicit a systemic anti-inflammatory response.

Subjects were randomly (1:1) allocated to receive active treatment or placebo (sham treatment). Both active and placebo groups were well balanced at baseline. All subjects received treatments on Days 1, 2, and 14, and then every 28 days thereafter until the end of study, or a minimum of 22 weeks. Neither the subjects nor their doctors knew whether they were receiving real or placebo treatment (double-blind).

Our results show that although the ACCLAIM trial of Celacade immunotherapy did not meet its primary endpoint of reducing the risk of the composite of mortality or CV hospitalization, pre-specified subgroup analysis provided evidence that Celacade immunotherapy significantly reduced this risk in subjects who had not reached more advanced stages of HF.

For example, in the 689 NYHA class II patients in the study, Celacade immunotherapy reduced the risk of mortality or CV hospitalization by 39% (P=0.0003). Additional exploratory analysis in combined subgroups totaling over 70% of ACCLAIM study subjects indicated that Celacade immunotherapy was significantly more beneficial than placebo in reducing risk of mortality or morbidity.

Celacade immunotherapy was safe and well tolerated, and there was no evidence of detrimental effects on blood pressure and heart rate when used in combination with standard therapy (including vasoactive neurohormonal antagonists). Further, there was no difference in infection-related adverse events as compared to placebo, and no evidence of tolerability issues in subjects with other health problems in addition to HF.

In conclusion, the ACCLAIM trial findings support the hypothesis that inflammation participates in the progression of the HF syndrome. More importantly, the ACCLAIM trial provides evidence that Celacade immunotherapy is effective in patients who have not reached more advanced stages of heart failure, supporting the concept that exploiting the physiological anti-inflammatory response to cells undergoing apoptosis has substantial therapeutic potential. Finally, the ACCLAIM results provide a strong basis for moving forward with a confirmatory study to definitively assess the clinical utility of Celacade in this patient population.

http://www.worldcardio2006.org

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underHeart

Keep reading

Heart

Early sexual abuse increases heart risks

Women who were repeatedly sexually abused as girls have a 62 percent higher risk of heart problems later in life compared with women who were not abused, U.S. researchers said on Sunday. The findings, presented at…

2 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.